|
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) |
|
Enanta Pharmaceuticals Inc
ENTA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Enanta Pharmaceuticals Inc's sales fell
by -22.84 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1886
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Enanta Pharmaceuticals Inc net loss increased from $-28 millions, to $-29 millions in IV. Quarter 2024,
• More on ENTA's Growth
|
|
Enanta Pharmaceuticals Inc realized a net loss in trailing twelve months.
Enanta Pharmaceuticals Inc realized cash reduction of $ -2.27 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.73.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.96.
• More on ENTA's Valuation
|
|
|
|
|
Enanta Pharmaceuticals Inc realized net loss in trailing twelve months.
Enanta Pharmaceuticals Inc realized cash outflow of $ -2.27per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.73.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.96.
Enanta Pharmaceuticals Inc Price to Book Ratio is at 0.91 lower than Industry Avg. of 428.32. and higher than S&P 500 Avg. of 0.02
• More on ENTA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com